Metabolite biomarkers in lung cancer: unlocking the potential of body fluid analysis for early detection and prognosis-a narrative review.

ABSTRACT:

Background and objective

Lung cancer is a leading cause of cancer-related mortality, due to delayed diagnosis and the complexity of selecting the optimal treatment method, given the genetic diversity and heterogeneity of the disease. Traditional invasive techniques, such as tissue biopsy, carry risks of severe complications and are often costly. Therefore, there is increasing interest in non-invasive alternatives, particularly liquid biopsy. This review aims to propose promising circulating metabolite biomarkers for lung cancer and their clinical applications.

Methods

A PubMed search [2014-2024] was conducted, focusing on fluid-based, non-invasive samples such as blood, urine, pleural effusion, and bronchoalveolar lavage fluid. Only English-language articles relevant to lung

SUBMITTER: Kim SM 

PROVIDER: S-EPMC12541831 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature